Compare Cassava Sciences Inc (FLNA) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Stanley Black & Decker, Inc. — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Stanley Black & Decker, Inc. trades at $88.65 (market cap $13.47B). The key difference: Stanley Black & Decker, Inc. is far larger — about 341.9× Cassava Sciences Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.77% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Stanley Black & Decker, Inc. for 62 Days on average.
| FLNA | SWK | |
|---|---|---|
Market Cap | $39.40M | $13.47B |
Volume | 759,018 | 2,859,744 |
Sector | Health | Industrials |
52-Week High | $4.64 | $104.00 |
52-Week Low | $0.68 | $62.12 |
Typical Hold Time | 37 Days | 62 Days |
Enterprise Value | -$43.28M | $17.63B |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Stanley Black & Decker (SWK) trades at $88.49, up 0.2% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $1.57 beating expectations of $1.21, and projected 2026 net income margin of 4.06%. Valuation metrics appear reasonable with P/E of 21.8 and P/S of 0.89. Recent news highlights new product launches and dividend consistency as a Dividend King.
SWK presents a mixed outlook with strong brand positioning and margin improvement initiatives offset by technical weakness. The consensus price target of $93.00 suggests 5% upside potential, but investors face execution risks amid competitive pressures and ongoing operational challenges. The stock's dividend history provides income stability while awaiting fundamental improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
